GSK Tackles Rotarix Risks Head On, Clearing Way For Panel’s Support
Executive Summary
With a positive advisory committee recommendation, GlaxoSmithKline's rotavirus vaccine Rotarix is proving to be a successful example of handling a known risk factor by working closely with FDA, prospectively assessing the risk potential and developing a comprehensive pharmacovigilance plan